Long-term stimulant medication treatment of attention-deficit/hyperactivity disorder: results from a population-based study.
about
Long-Term Outcomes with Medications for Attention-Deficit Hyperactivity DisorderChanges in behavior as side effects in methylphenidate treatment: review of the literatureChildhood ADHD and risk for substance dependence in adulthood: a longitudinal, population-based studyChiropractic care for paediatric and adolescent Attention-Deficit/Hyperactivity Disorder: A systematic reviewSpecific Genes Associated with Adverse Events of Methylphenidate Use in the Pediatric Population: A Systematic Literature ReviewDopamine transporter genotype and stimulant side effect factors in youth diagnosed with attention-deficit/hyperactivity disorder.Does pharmacotherapy for attention-deficit/hyperactivity disorder predict risk of later major depression?Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHDADHD, stimulant treatment, and growth: a longitudinal study.Using stimulants for attention-deficit/hyperactivity disorder: clinical approaches and challenges.Less discontinuation of ADHD drug use since the availability of long-acting ADHD medication in children, adolescents and adults under the age of 45 years in the Netherlands.A two-site randomized clinical trial of integrated psychosocial treatment for ADHD-inattentive type.Attention-deficit hyperactivity disorder (ADHD): does new research support old concepts?Academic, behavioral, and cognitive effects of OROSĀ® methylphenidate on older children with attention-deficit/hyperactivity disorderAttention-deficit hyperactivity disorder in children with high intelligence quotient: results from a population-based studyAnnual Research Review: New frontiers in developmental neuropharmacology: can long-term therapeutic effects of drugs be optimized through carefully timed early intervention?The strengths and difficulties questionnaire as a predictor of parent-reported diagnosis of autism spectrum disorder and attention deficit hyperactivity disorder.Canine-assisted therapy for children with ADHD: preliminary findings from the positive assertive cooperative kids study.Exploring stimulant treatment in ADHD: narratives of young adolescents and their parents.Divergence by ADHD subtype in smoking cessation response to OROS-methylphenidate.Racial differences in parental reports of attention-deficit/hyperactivity disorder behaviorsAttention deficit hyperactivity disorder subtypes and symptom response in adults treated with lisdexamfetamine dimesylate.Problematic Peer Functioning in Girls with ADHD: A Systematic Literature ReviewPersonalized Medication Response Prediction for Attention-Deficit Hyperactivity Disorder: Learning in the Model Space vs. Learning in the Data Space.Guanfacine Extended Release: A New Pharmacological Treatment Option in Europe.Pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: clinical strategiesStimulant medication treatment of target behaviors in children with autism: a population-based study.A randomised controlled trial of the Neuro Emotional Technique (NET) for childhood Attention Deficit Hyperactivity Disorder (ADHD): a protocol.Global issues related to the impact of untreated attention-deficit/hyperactivity disorder from childhood to young adulthood.Mortality, ADHD, and psychosocial adversity in adults with childhood ADHD: a prospective study.Improving psychostimulant adherence in children with ADHD.Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD.Adult attention-deficit/hyperactivity disorder: Associations between subtype and lifetime substance use - a clinical study.Analysis of individual items on the attention-deficit/hyperactivity disorder symptom rating scale in children and adults: the effects of age and sex in pivotal trials of lisdexamfetamine dimesylate.Childhood Attention-Deficit/Hyperactivity Disorder, Sex, and Obesity: A Longitudinal Population-Based Study.The costs and benefits of diagnosis of ADHD: commentary on Holden et alMinimizing adverse events while maintaining clinical improvement in a pediatric attention-deficit/hyperactivity disorder crossover trial with dextroamphetamine and methylphenidate.Long-term treatment of ADHD with stimulants: a large observational study of real-life patients.The role of alpha2-adrenergic agonists in attention-deficit/hyperactivity disorder.Managing ADHD across the lifespan in the primary care setting.
P2860
Q22241421-89D364A5-6AC9-4875-AC0D-9233DF96AD79Q28078623-328C8B45-D307-498D-A174-E18C55DC96F6Q28542571-C6AD32B5-F5D6-467A-A555-A1EEFE73154DQ30495118-8CD2CBFB-EA06-4F64-8415-F0A688B29AE5Q33777131-BB01B4EF-494F-4175-ABE0-94D55658D41AQ33799533-F840B66A-AF61-463D-A223-1D4DB35FFDA3Q34112070-4DF44B9D-997D-401E-8249-7C02BD7CB6C0Q34183741-B9E6322C-86D7-4913-B244-928C635D82AFQ34263102-A63F409F-D505-47FC-A4C1-242B0AABD4BEQ34362939-DC1F4932-6784-420A-BFA2-264EEBB1464BQ34400595-20C604BE-ED5C-4A71-931F-A4DCD74B67A7Q34572762-3377B420-DFCB-45A7-90C3-0C5A89EF9D58Q34801521-24422DFD-8CA4-42F5-B054-F5596FF0B7CDQ34832003-DE26713A-13DA-40F3-8B8D-EC738634C91DQ34985206-90982EBF-A09C-4BA8-BFAE-AD268C9357B4Q35046638-0F212522-622E-4037-B4ED-EE5E76B0AFEBQ35061037-DB0DB96F-5A49-402C-A8C6-8D574D77DE79Q35142371-AE804666-A14D-46F7-83A3-33DBB414709FQ35146170-CEA5A9D9-A58B-47E3-B29A-3F9BD541DD19Q35231025-2DDDDF28-1FB5-4C00-9A03-6F890B7A9E1BQ36093111-BB7A7766-3C9E-4051-BE95-8C2C5D3DD9A8Q36100165-2D87ED73-6044-4B9D-B789-96222F402E08Q36199669-F1CD8471-AE43-4BCA-9922-A7F32968AC5BQ36356229-FBBB7C9C-FEE3-4BCB-8617-15FB9343C2DAQ36446854-E5A6BECE-E36E-4432-B5E2-301D850A7B57Q36740445-D4CB1CD5-9B68-4055-AADA-595A9C80C8BDQ36978496-A5250751-7AF6-45CE-AB16-DCE84EF64857Q37107121-3918376E-0441-4F68-81B6-086E1F38D1F1Q37282163-0986F08E-278A-4D22-9D16-6CC29A47BB91Q37290084-2B3A925A-0D11-40DB-BAAD-3BAEE235BA71Q37301222-D565C342-040A-4CF0-8E87-9EBEDA9DCED3Q37376330-7FAB2AFF-7120-45F0-B910-450ECDE3DF18Q37384261-5A73CBDF-0D8D-413C-85A7-AE7148D04379Q37391143-4A88C1C1-FCD9-4C0F-9A0F-44A9CACA0436Q37604948-1CA4C4D5-DDDA-47C0-A52D-FC4BCF73708BQ37615841-6A60FB1A-D623-42E5-9F03-BA4925F673D6Q37712616-B74E8068-F87D-4245-B0E7-DD72AAC94DE1Q37772707-CE39E1AD-F4D0-4A76-A7ED-11782E8B181FQ37791316-D0AF26E1-23B0-4DCC-8130-561630D9CB8BQ37929495-E2B773D8-56D7-4DE1-B2FB-87B2399FF1E5
P2860
Long-term stimulant medication treatment of attention-deficit/hyperactivity disorder: results from a population-based study.
description
2006 nĆ® lÅ«n-bĆ»n
@nan
2006 Õ©ÕøÖÕ”ÕÆÕ”Õ¶Õ« ÕÕ„ÕæÖÕøÖÕ”ÖÕ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕøÖÕ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ ÕµÖ
Õ¤ÕøÖÕ”Õ®
@hyw
2006 Õ©Õ¾Õ”ÕÆÕ”Õ¶Õ« ÖÕ„ÕæÖÕ¾Õ”ÖÕ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕ¾Õ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ Õ°ÕøÕ¤Õ¾Õ”Õ®
@hy
2006幓ć®č«ę
@ja
2006幓č«ę
@yue
2006幓č«ę
@zh-hant
2006幓č«ę
@zh-hk
2006幓č«ę
@zh-mo
2006幓č«ę
@zh-tw
2006幓č®ŗę
@wuu
name
Long-term stimulant medication ...... from a population-based study.
@ast
Long-term stimulant medication ...... from a population-based study.
@en
Long-term stimulant medication ...... from a population-based study.
@nl
type
label
Long-term stimulant medication ...... from a population-based study.
@ast
Long-term stimulant medication ...... from a population-based study.
@en
Long-term stimulant medication ...... from a population-based study.
@nl
prefLabel
Long-term stimulant medication ...... from a population-based study.
@ast
Long-term stimulant medication ...... from a population-based study.
@en
Long-term stimulant medication ...... from a population-based study.
@nl
P2093
P1476
Long-term stimulant medication ...... from a population-based study.
@en
P2093
Amy L Weaver
Cynthia L Leibson
Robert C Colligan
Slavica K Katusic
William J Barbaresi
P356
10.1097/00004703-200602000-00001
P577
2006-02-01T00:00:00Z